Paeoniflorin alleviated STZ-induced diabetic retinopathy via regulation of the PDI/ADAM17/MerTK pathway

Xiuting Qi1, Haiyue Guo1, Xinyue Xia2

  • 1Department of Pharmacology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu 211100, China.

PubMed
Abstract

Insights

Paeoniflorin alleviates diabetic retinopathy by reducing inflammation. It modulates the PDI/ADAM17/MerTK pathway, enhancing MerTK signaling and suppressing inflammatory markers in diabetic eye disease.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss, characterized by apoptotic cell accumulation and inflammation.
  • Mer tyrosine kinase (MerTK) is crucial for retinal homeostasis, but its function is impaired by ADAM17-mediated cleavage in DR.
  • Targeting ADAM17 activity and promoting MerTK signaling offers a potential therapeutic strategy for DR.

Purpose of the Study:

  • To investigate the therapeutic potential of paeoniflorin in a diabetic retinopathy (DR) mouse model and high-glucose-induced ARPE-19 cells.
  • To elucidate the underlying molecular mechanisms involving the PDI/ADAM17/MerTK signaling pathway.

Main Methods:

  • Established DR models using streptozotocin (STZ) in mice and high-glucose (HG) in ARPE-19 cells.
  • Analyzed key signaling molecules via western blotting and immunohistochemistry.
  • Investigated the effects of paeoniflorin on PDI, ADAM17, MerTK, SOCS3, and MMP9 expression and phosphorylation.

Main Results:

  • Hyperglycemia induced apoptotic cell accumulation and microvascular damage, reducing MerTK and increasing ADAM17 phosphorylation.
  • Paeoniflorin upregulated protein disulfide isomerase (PDI), suppressed ADAM17, and enhanced MerTK phosphorylation in DR models.
  • Paeoniflorin treatment increased SOCS3 and decreased MMP9 levels, indicating reduced inflammation.

Conclusions:

  • Paeoniflorin demonstrates therapeutic potential for diabetic retinopathy.
  • The drug alleviates DR by suppressing inflammation via the PDI/ADAM17/MerTK signaling pathway.
  • Paeoniflorin represents a promising agent for managing DR by restoring MerTK function and reducing inflammatory mediators.